A central challenge in relapsed/refractory follicular lymphoma is determining a treatment sequence that maximizes current ...

New data show 100% (6/6) objective response rate (ORR) with EO2463 in previously untreated patients with follicular lymphoma needing treatment in combination with rituximab (SIDNEY Cohort 3) -- Of the ...

The addition of epcoritamab to standard therapy significantly improved PFS for patients with relapsed or refractory ...

"Epcoritamab and R 2 is a novel chemotherapy-free fixed-duration therapy that is suitable for outpatient administration and, ...

New three-year follow-up results from the TRANSCEND FL trial show that patients with relapsed or refractory follicular ...

The EPCORE FL-1 trial evaluated epcoritamb plus lenalidomide and rituximab versus plus lenalidomide and rituximab for ...

Epcoritamab addition to R2 significantly improves progression-free survival and overall response rates in relapsed follicular ...

Generally follicular lymphomas are slow growing or indolent but sometimes they undergo many transformation and start growing very fast and turn into high grade lymphomas and start behaving as diffuse ...

In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction ...

In this phase 2 study, researchers sought to determine whether cytoreductive treatment with rituximab followed by epcoritamab would deepen responses and lower risk of cytokine release syndrome.

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades. Yet up to 20% of patients develop early progression after starting ...

New data show 100% (6/6) objective response rate (ORR) with EO2463 in previously untreated patients with follicular lymphoma needing treatment in ...